Nelarabine

Nucleoside Metabolic Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Nelarabine is an ofp drug in the Nucleoside Metabolic Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors. Recorded indications include Precursor T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia.

• Approval status: ofp (first approved 2005 by the FDA).
• Drug class: Nucleoside Metabolic Inhibitor.
• Mechanism of action: Nucleic Acid Synthesis Inhibitors.
• Indications: Precursor T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia.
• ATC code: L01BB07 (Purine analogues).
• Molecular formula: C11H15N5O5; molecular weight 297.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Precursor T-cell lymphoblastic lymphoma
• T-cell acute lymphoblastic leukemia

Contraindications (20)

• Anemia
• Breastfeeding (mother)
• Chemotherapy-Induced Hyperuricemia
• Dehydration
• Demyelination
• Drowsy
• Hepatic failure
• Hyperbilirubinemia
• Impaired renal function disorder
• Intrathecal injection of chemotherapeutic agent
• Mental handicap
• Neutropenic disorder
• Peripheral demyelinating neuropathy
• Peripheral nerve disease
• Pregnancy, function
• Radiation Therapy of Cranium
• Radiation Therapy of Vertebral Column
• Seizure disorder
• Severe Leukopenia
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Nucleic Acid Synthesis Inhibitors
• Established pharmacologic class: Nucleoside Metabolic Inhibitor

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2007-08-22	EMA	—	Sandoz Pharmaceuticals d.d.	Yes
2005-10-28	FDA	—	NOVARTIS PHARMS CORP	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01BB07	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Purine analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelopathy	268.0
Peripheral sensory neuropathy	195.9
Peripheral motor neuropathy	163.4
Guillain-Barre syndrome	162.5
Neurotoxicity	154.5
Febrile neutropenia	117.8
Fibrinous bronchitis	100.1
Subacute combined cord degeneration	88.9
Neuropathy peripheral	85.2
Scedosporium infection	80.0
Polyneuropathy	69.0
Hypertriglyceridaemia	68.4

Chemical structure

• Molecular formula: C₁₁H₁₅N₅O₅
• Molecular weight: 297.27 g/mol
• CAS number: 121032-29-9
• InChIKey: IXOXBSCIXZEQEQ-UHTZMRCNSA-N
• PubChem CID: 135499520

COC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C2=NC(N)=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nelarabine used for?

DrugCentral lists the following indications for Nelarabine: Precursor T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia.

How does Nelarabine work?

Nelarabine is classified as Nucleic Acid Synthesis Inhibitors.

When was Nelarabine first approved?

Nelarabine was first approved by the FDA in 2005.

What drug class does Nelarabine belong to?

Nelarabine is in the Nucleoside Metabolic Inhibitor class.

What is the chemical formula of Nelarabine?

Nelarabine has the molecular formula C11H15N5O5 and a molecular weight of 297.27 g/mol.

Sources

• DrugCentral drug card 1892 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201112 — compound record and bioactivity
• PubChem CID 135499520 — chemical identifiers
• DrugBank DB01280 — drug record
• FDA UNII 0Z99WX0GPF — substance identity
• DailyMed: FDA labels for Nelarabine — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.